Nervonic Acid Cyclodextrin Complex for ALD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for adrenoleukodystrophy (ALD) are limited, with allogeneic hematopoietic stem cell transplantation having serious complications and Lorenzo's oil showing cardiotoxicity and unclear benefits, necessitating a more effective and safer therapeutic option.
Innovation Solution
A pharmaceutical composition comprising nervonic acid and a cyclodextrin excipient, which can be administered in both solid and liquid dosage forms, to treat or prevent ALD by reducing the accumulation of very long chain fatty acids and improving mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplantation is used to treat ALD, then therapeutic effect is improved, but serious complications and risks occur
Solution Approach 1:
The patent extracts and addresses the specific harmful aspect (transplantation complications) by providing an alternative treatment approach using oral nervonic acid supplementation that bypasses the need for stem cell transplantation, thereby eliminating transplantation-related risks while treating the underlying ALD pathology
Solution Approach 2:
The patent introduces cyclodextrin as a solubilizing agent that mediates the delivery of nervonic acid, enabling effective oral administration and absorption of the fatty acid supplement, which serves as an intermediary therapeutic approach between diet and transplantation
2Quantity of substance
If Lorenzo's oil is administered to treat ALD, then plasma VLCFA levels are reduced, but cardiotoxicity and unclear benefits occur
Solution Approach 1:
The patent extracts only the beneficial component (nervonic acid) from Lorenzo's oil while eliminating the harmful components (erucic acid and other fatty acids) that cause cardiotoxicity, providing a purified therapeutic approach that maintains VLCFA reduction benefits without cardiac side effects
Solution Approach 2:
The patent changes the chemical composition parameters by using pure nervonic acid instead of the mixed fatty acid composition of Lorenzo's oil, and optimizes the dosage form through cyclodextrin complexation to achieve therapeutic effects with improved safety profile
3Reliability
If nervonic acid is administered to reduce VLCFA accumulation, then therapeutic benefit is achieved, but solubility and bioavailability challenges occur
Solution Approach 1:
The patent introduces cyclodextrin as a solubilizing intermediary that forms inclusion complexes with nervonic acid, dramatically improving its aqueous solubility and oral bioavailability, thereby enabling effective delivery of the therapeutic agent
Solution Approach 2:
The patent creates a composite pharmaceutical system consisting of nervonic acid complexed with cyclodextrin, combining the therapeutic fatty acid with a solubilizing carrier molecule to achieve both therapeutic efficacy and improved pharmacokinetic properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively decreases the levels of toxic very long chain fatty acids and increases ATP production, reducing oxidative stress and potentially stabilizing or slowing the progression of ALD, with a safer profile compared to existing treatments.
Implementation Method 1
pharmaceutical compositions that include nervonic acid and a cyclodextrin
Data Source
AI summary
Pharmaceutical compositions including nervonic acid or a pharmaceutically acceptable salt thereof and a cyclodextrin. Methods of treating a subject having or at risk of having adrenoleukodystrophy and/or a neurological disease by administering a pharmaceutical composition of the present disclosure to the subject.